Jazz Pharmaceuticals Public (Nasdaq: JAZZ) reported earnings on May 7. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), Jazz Pharmaceuticals Public beat expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue grew significantly. Non-GAAP earnings per share grew significantly. GAAP earnings per share expanded significantly.

Margins contracted across the board.

Revenue details
 Jazz Pharmaceuticals Public chalked up revenue of $196.2 million. The 10 analysts polled by S&P Capital IQ anticipated revenue of $190.9 million on the same basis. GAAP reported sales were 81% higher than the prior-year quarter's $108.4 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $1.37. The 13 earnings estimates compiled by S&P Capital IQ anticipated $1.35 per share. Non-GAAP EPS of $1.37 for Q1 were 51% higher than the prior-year quarter's $0.91 per share. GAAP EPS of $0.71 for Q1 were 48% higher than the prior-year quarter's $0.48 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 86.1%, 620 basis points worse than the prior-year quarter. Operating margin was 34.7%, 370 basis points worse than the prior-year quarter. Net margin was 22.1%, 340 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $204.5 million. On the bottom line, the average EPS estimate is $1.48.

Next year's average estimate for revenue is $830.0 million. The average EPS estimate is $5.96.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 233 members out of 296 rating the stock outperform, and 63 members rating it underperform. Among 73 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 58 give Jazz Pharmaceuticals Public a green thumbs-up, and 15 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Jazz Pharmaceuticals Public is buy, with an average price target of $71.36.